What Is Semaglutide? A Complete Guide to Ozempic and Wegovy
- What it is: Semaglutide is a GLP-1 receptor agonist that mimics a natural hormone to reduce appetite and control blood sugar
- Brand names: Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral diabetes)
- Weight loss: Clinical trials showed 15-17% body weight loss on average over 68 weeks
- How it’s taken: Weekly injection (Ozempic/Wegovy) or daily pill (Rybelsus)
- Side effects: Nausea is most common (44%), usually improves after 4-8 weeks
What is semaglutide?
Semaglutide is a medication classified as a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking a hormone your body naturally produces after eating, which helps regulate blood sugar and reduce appetite.
Developed by Novo Nordisk, semaglutide is marketed under three brand names:
- Ozempic: FDA-approved for type 2 diabetes
- Wegovy: FDA-approved for chronic weight management
- Rybelsus: Oral tablet form for type 2 diabetes
The injectable forms (Ozempic and Wegovy) come in pre-filled pens for once-weekly self-injection. Rybelsus is a daily tablet that must be taken on an empty stomach with minimal water.
Important: While Ozempic and Wegovy contain the same active ingredient, they’re FDA-approved for different purposes and have different dosing. Ozempic is often prescribed off-label for weight loss when Wegovy isn’t available.
Ozempic vs. Wegovy vs. Rybelsus
Understanding the differences between these three brands helps you know which might be right for you.
| Feature | Ozempic | Wegovy | Rybelsus |
|---|---|---|---|
| FDA Approval | Type 2 diabetes | Weight loss | Type 2 diabetes |
| Form | Weekly injection | Weekly injection | Daily pill |
| Max Dose | 2 mg | 2.4 mg | 14 mg |
| Approved | Dec 2017 | June 2021 | Sept 2019 |
Insurance implications
Insurance typically covers Ozempic for diabetes with prior authorization, but coverage for Wegovy (weight loss) varies widely. Many people get Ozempic prescribed off-label for weight loss when their insurance won’t cover Wegovy.
How semaglutide works
Semaglutide mimics GLP-1, a hormone your body releases after eating. Natural GLP-1 breaks down within minutes, but semaglutide is engineered to last about a week.
The GLP-1 mechanism
When you eat, your intestines release GLP-1, which:
- Signals your pancreas to release insulin
- Slows stomach emptying so you feel full longer
- Acts on brain receptors to reduce hunger
- Reduces glucagon release (which raises blood sugar)
Three main benefits
1. Blood sugar control: Stimulates insulin release when blood sugar is high, reducing HbA1c levels by 1-2% in most patients.
2. Weight loss: Reduces appetite by acting on brain hunger centers. Slows digestion so you feel satisfied with less food.
3. Cardiovascular benefits: Clinical trials have shown reduced risk of heart attack, stroke, and cardiovascular death in people with type 2 diabetes.
Weight loss results from clinical trials
The STEP (Semaglutide Treatment Effect in People with Obesity) trials provide the most comprehensive data on semaglutide for weight loss.
STEP 1 trial results
In the landmark STEP 1 trial with 1,961 participants:
- Average weight loss: 14.9% of body weight (vs. 2.4% placebo)
- Participants losing ≥10%: 69% on semaglutide (vs. 12% placebo)
- Participants losing ≥20%: 32% on semaglutide (vs. 1.7% placebo)
Results were measured at 68 weeks (about 16 months) on the full 2.4mg dose.
What to expect
Weight loss typically follows this pattern:
- Weeks 1-4: Reduced appetite, minimal weight loss during dose titration
- Months 2-6: Steady weight loss of 1-2% per month
- Months 6-12: Weight loss continues but slows
- Month 12+: Weight typically stabilizes at new lower level
Side effects and safety
Most semaglutide side effects are gastrointestinal and tend to improve over time.
Common side effects
| Side Effect | Semaglutide | Placebo |
|---|---|---|
| Nausea | 44% | 17% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
These side effects are most common during dose increases and typically improve within 4-8 weeks.
Serious risks (rare)
- Pancreatitis: Less than 1% in trials. Stop if severe abdominal pain occurs.
- Gallbladder problems: 1-2% risk, related to rapid weight loss.
- Thyroid tumors: Boxed warning based on rodent studies. No human signal after 5+ years.
For detailed information, see our complete guide to semaglutide side effects.
Cost and access
Semaglutide costs vary significantly based on insurance coverage and which brand you use.
List prices (without insurance)
- Ozempic: ~$900-1,000/month
- Wegovy: ~$1,300-1,400/month
- Rybelsus: ~$900-1,000/month
- Compounded semaglutide: $200-500/month (varies by provider)
Ways to save
- Manufacturer savings cards: Can reduce costs to $25/month for eligible patients
- Insurance prior authorization: Worth appealing if initially denied
- Compounded semaglutide: Available through telehealth providers at lower cost
For detailed pricing, see our semaglutide cost guide.
Ready to start semaglutide?
Compare telehealth providers offering semaglutide prescriptions.
See provider reviews →Frequently asked questions
The bottom line
Semaglutide represents a significant advancement in treating both type 2 diabetes and obesity. With average weight loss of 15% and proven cardiovascular benefits, it’s become one of the most prescribed medications in the country.
The main barriers are cost and side effects. Insurance coverage varies widely, and the GI side effects (while usually temporary) can be challenging during the first few months.
If you’re considering semaglutide, talk to your doctor about whether it’s appropriate for your situation, and check out our provider reviews to find a reputable telehealth option.
References
1. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. View source
2. FDA. Wegovy (semaglutide) Prescribing Information. View source
3. Marso SP, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM.